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ABSTRACT 
 
Cigarette smoke (CS) exposure is the leading cause of preventable death in the 
United States contributing to over 480,000 deaths a year with over 300 billion dollars in 
CS related costs spent per year. While the dangers of CS exposure have been studied and 
characterized for decades being largely attributed to reactive oxygen species and 
oxidative stress, increasing evidence suggests that reactive aldehydes in CS, specifically 
the α,β-unsaturated aldehyde acrolein, are responsible for many of the negative 
pathologies associated CS exposure. Previous work has shown that acrolein can bind 
directly to a number of cellular proteins containing redox sensitive cysteine residues. 
The non-receptor tyrosine kinase Src contains nine cysteine residues and is known to be 
activated in response to CS and oxidative stress. Despite being the first characterized 
and one of the most widely studied oncogenes, the exact mechanism for Src activation 
remains unclear. In the current studies we examined the effects of acrolein on Src 
activation and the resulting outcomes on the lung epithelium in an effort to better 
understand how reactive electrophiles in CS contribute to the development of lung 
disease.  
 To determine the effects of acrolein on Src activation, we first exposed NCI-H292 
cells to acrolein and measured activity by western blot. We observed an increase in Src 
activity detected by an increase in Src phosphorylation at Y416 and an increase in 
phosphorylation of Src target proteins Caveolin1 and p120. Interestingly the increase in 
activation occurred without dephosphorylation of the inhibitory phosphorylated tyrosine 
Y527. Using biochemical-labeling strategies we identified Src as a direct target of 
acrolein adduction in vitro and in vivo, and we used mass spectrometry to confirm 
acrolein adduction to cysteine residues C245, C277 and C487, all which have been 
implicated in a redox dependent Src activation mechanism. Furthermore, increased Src 
activity following acrolein exposure was confirmed using an in vitro kinase activity 
assay and recombinant Src in a cell free system. 
 To study the effects of acute acrolein exposure on lung epithelial function we 
exposed cultured mouse tracheal epithelial cells (MTECs) to acrolein and show impaired 
epithelial barrier function, measured by a decrease in trans epithelial resistance (TER) 
and increased epithelial permeability to FITC-dextran, which could be prevented using 
the Src inhibitor PP2. Src inhibition also attenuated acrolein-induced loss of E-cadherin 
and ZO-1. Acute exposure of C57BL/6 mice to acrolein (5 ppm for 4 hrs) led to increased 
epithelial permeability, measured by enhanced leakage of i.v. injected FITC-dextran into 
the airspaces, and induction of HO-1 in the lung while chronic acrolein exposure resulted 
features of epithelial to mesenchymal transition including a reduction of E-cadherin, 
increased vimentin, increased expression of MMP9 and increased collagen deposition. 
Chronic acrolein exposure in vitro resulted in a reduction of E-cadherin that could be 
prevented using the Src inhibitor AZD0530.  
Together our studies demonstrate that Src is a direct target for acrolein and plays 
an important role in epithelial alterations due to acrolein exposure. This work provides 
further insight into a potential mechanism involved in the development of cigarette 
smoke related disease and could provide a potential target for novel therapeutics.  
 ii 
ACKNOWLEDGEMENTS 
First I want to thank my advisor Albert van der Vliet for the opportunity to work in his 
laboratory over the past four years. During that time he has pushed me to become a better 
scientist, researcher and writer. I’m grateful for all of the time and effort he has spent 
working with me to help me reach my goals. I have thank our wonderful lab technicians 
Milena and Aida for showing me everything I needed to know about laboratory when I 
first joined and for always being there to lend a helping hand with experiments or to 
explain protocols or teach me something new. I need to thank Ying Wai Lam for all of 
his expertise in mass spectrometry and for helping guide me through that process. I want 
to thank the other members of the van der Vliet laboratory, graduate students Andrew 
Little and Chris Dustin, as well as current postdoctoral fellows Dr. David Heppner and 
Dr. Karamatullah Danyal. I could not imagine working in a better lab with such great 
people. Thank you for making my time at UVM such as positive experience. Finally I 





TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS ................................................................................................ ii 
LIST OF FIGURES ............................................................................................................ v 
CHAPTER 1: LITERATURE REVIEW ............................................................................ 1 
1.1 Cigarette smoke ..................................................................................................................... 1 
1.2 Acrolein ................................................................................................................................. 3 
1.3. Src ......................................................................................................................................... 6 
1.4 Current Studies .................................................................................................................... 10 
1.5 References ........................................................................................................................... 12 
CHAPTER 2: ACROLEIN REDUCES EPITHELIAL BARRIER FUNCTION 
THROURGH SRC ACTIVATION .................................................................................. 15 
2.1. Abstract ............................................................................................................................... 15 
2.2. Introduction ........................................................................................................................ 17 
2.3. Methods .............................................................................................................................. 20 
2.4. Results ................................................................................................................................ 26 
2.5. Discussion ........................................................................................................................... 30 
2.6. Figures ................................................................................................................................ 33 
2.7 References ........................................................................................................................... 41 




3.1. Abstract ............................................................................................................................... 43 
3.2. Introduction ........................................................................................................................ 45 
3.3. Methods .............................................................................................................................. 48 
3.4. Results ................................................................................................................................ 53 
3.5. Discussion ........................................................................................................................... 60 
3.6. Figures ................................................................................................................................ 64 
3.7 References ........................................................................................................................... 77 
CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS ........................................... 80 
4.1 Summary .............................................................................................................................. 80 
4.2 Future Directions ................................................................................................................. 83 




LIST OF FIGURES 
 
Figure              Page 
Figure 1.1 Effects of cigarette smoke on the lung epithelium.............................................2 
Figure 1.2 Formation of cysteine to lysine cross links through acrolein.............................4 
Figure 1.3 Effects of Src activation on the lung epithelium................................................7 
Figure 2.1. Inhibition of Src prevents loss of epithelial barrier function following 
acrolein exposure...............................................................................................................33 
 
Figure 2.2. Acute acrolein exposure decreases lung epithelial barrier function in vivo....34 
Figure 2.3. Src knockdown by siRNA prevents loss of E-cadherin at the cell 
membrane...........................................................................................................................35 
 
Figure 2.4. Acrolein exposure reduces E-cadherin surface labeling.................................36 
Figure 2.5. Chronic acrolein exposure in MTECs.............................................................37 
Figure 2.6. Chronic acrolein exposure in vivo..............................................................38,39 
Figure 2S1. Alterations in internalized E-cadherin are not detected following acrolein 
treatment............................................................................................................................40 
Figure 3.1. Acrolein increases Src phosphorylation and activation in vitro......................64 
Figure 3.2. Acrolein induced Src phosphorylation does not depend on EGFR kinase 
activity................................................................................................................................65 
 
Figure 3.3. Acute acrolein exposure induces HO-1 in vivo...............................................66 
Figure 3.4. Acrolein induced HO-1 expression is mediated through Src..........................67 
Figure 3.5. Src activity is increased after exposure to acrolein.........................................68 
Figure 3.6 Acrolein adducts on Src can be detected in vitro and in vivo...........................69 
 
 vi 
Figure 3.7. Cysteine modifications by acrolein are reversed over time.............................70 
Figure 3.8. Acrolein adducts are detectable by mass spectrometry...................................71 
 
Figure 3.9 Prosposed Src activation mechanism...............................................................72 
 
Figure 3S1. Cell viability after acrolein exposure.............................................................73 
Figure 3S2. Representative LC-MS/MS spectra................................................................74 
Figure 3S3. Dimedone pretreatment does not reduce biotin hydrazide labeling...............75 




CHAPTER 1: LITERATURE REVIEW 
1.1 Cigarette smoke 
Over 480,000 people die every year as a result of cigarette smoke (CS) exposure 
making smoking the 3rd leading cause of preventable death in the United States with 
associated health care costs rising as high as 300 billion dollars spent per year [1]. 
Exposure to cigarette smoke increases the risk of developing lung cancer and COPD 
contributing to 90% of lung cancer related deaths and 80% of COPD related deaths [1]. 
Additionally, childhood exposure to CS is the only proven cause of asthma and can also 
result in worsening of asthma symptoms [2].  
Over 5,000 chemicals are produced through burning tobacco and interact with the 
lung epithelium in a solid phase and gaseous phase. Past research has attributed the 
negative effects of CS to the presence of reactive oxygen species (ROS) and increased 
oxidative stress within the cell. It’s been shown that CS induces DNA damage due to 
oxidative stress and that patients with COPD show an increase in protein oxidation in the 
lung compared to healthy lungs [3]. Additionally, the oxidative stress induced by CS is 
associated with an increase in the development of lung cancer [4]. Cigarette smoke 
exposure affects cellular systems in a variety of ways having both immunosuppressive 
and pro-inflammatory properties. CS impairs the innate immune response to allergens by 
inhibiting T-cell activation and impairing macrophage phagocytosis [5].  Exposure to 
cigarette smoke exposure also contributes to COPD and emphysema by repeatedly 
stimulating pro-inflammatory pathways and by promoting an increase in apoptosis 
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involving the generation of ceramide or by increasing cellular senescence involving the 
proteins p53 and p16 [6, 7]. Some of the effects of cigarette smoke on the lung epithelium 












       Figure 1.1 Effects of cigarette smoke on the lung epithelium.  
 
To better understand the effects of cigarette smoke, single components are often 
studied to determine their individual effects on cellular responses.  It was determined that 
acrolein and crotonaldehyde were the primary glutathione (GSH) adducts formed in lung 
epithelial cells following CS smoke exposure indicating that acrolein alters the 
availability of thiol based antioxidants and may be linked to signaling pathways involving 









of the same cellular responses as CS such as increased mucus metaplasia, collagen 
deposition, NF-κB activation, irritation to the respiratory tract, and altered host defense, 
and may be a primary contributing factor to the underlying signaling mechanisms 
involved in CS exposure[9, 10]. One classification scheme has separated chemicals of CS 
into two groups consisting of cancer causing and non-cancer hazards. Of the non-cancer 
hazards found in CS, acrolein was the most abundant chemical identified [11].  
1.2 Acrolein 
The α,β-unsaturated aldehyde acrolein (2-propenal) is the smallest unsaturated 
aldehyde and is produced through the incomplete combustion of organic matter including 
fossil fuels, wood stoves, and cooking oil [12]. The largest source of acrolein exposure 
that poses the greatest risk to human health is through the inhalation of cigarette smoke 
with concentrations in mainstream smoke ranging as high as 90 ppm, which is significant 
because levels as low as 0.5 ppm cause lacrimation while concentrations of 5.5 ppm 
cause irritation to the eyes and nose [13]. Using HPLC it was estimated that cigarette 
smoke exposure resulted in acrolein concentrations as high as 80 µM in respiratory tract 
lining fluid [14]. Acrolein exposure has been associated with cell signaling pathways 
involved in the development of COPD and is measured to be higher in the lungs of 
patients with asthma and COPD [15]. Acrolein is seen to mimic many of the same effects 
as CS including a suppressed innate macrophage response, suppressed host defense, and 
increased mucus hypersecretion, suggesting that acrolein is a major contributor to CS 
related pathologies [16-18].   
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Acrolein is classified as a soft electrophile based on the ability of its surrounding 
electron cloud to be highly polarizable creating an electron dense region near its carbonyl 
with an electron deficient region at its terminal β-carbon [19]. As a soft electrophile, 
acrolein primarily reacts with soft nucleophiles such as cysteine, lysine and histidine 
residues through a process known as Michael addition occurring though its terminal β-








 The cysteine sulfhydryl thiolate is one of the softest biological nucleophiles 
making it one of the most prominent targets of acrolein [19]. Previous work in the van 
der Vliet laboratory has shown through mass spectrometry that the majority of acrolein 
adducts in the cell occur on cysteine residues [20]. The carbonyl of acrolein is also 
reactive with the ability to form a Schiff base with the terminal amine of lysine residues 
and the DNA base deoxyguanosine [21]. The two reactive sites on acrolein allow for the 
formation of protein-protein cross-links through Michael addition to cysteine residues 
and subsequent Schiff base formation with lysine. If a cross link forms the subsequent 





Figure 1.2 Formation of cysteine to lysine cross links through acrolein. 
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lysine residue with regeneration of free cysteine that is detectable using mass 
spectrometry (Fig 1.2B) [22].  
One of the main detoxification mechanisms of acrolein is through conjugation 
with glutathione (GSH), which can occur with or without the use of a catalyst or enzyme 
[12]. Acrolein exposure has been shown to rapidly deplete cellular levels of GSH that are 
recoverable over time partially through increased synthesis of GSH [23]. Previous work 
in the van der Vliet laboratory has also shown that GSH plays a role in reversing protein 
alkylation demonstrated by the presence of more acrolein adducts in cells treated with the 
GSH synthesis inhibitor BSO and that reversal of acrolein adducts is not dependent on 
the actions of the 26S proteasome [23]. Additionally, mice expressing the enzyme 
glutathione S-transferase P (GSTP) showed fewer acrolein adducts over time compared to 
GSTP null mice suggesting that GSTP plays a role in the reversal of acrolein-protein 
adducts by promoting the adducts transfer and conjugation with GSH [24]. This has 
important implications for the use of electrophiles as a form of reversible signaling 
mechanism in the cell.  
Once acrolein is bound to GSH the conjugate begins degradation starting 
primarily in the liver where acrolein-bound GSH undergoes cleavage of its γ-glutamic 
acid then subsequent cleavage of glycine. Upon reaching the kidney the conjugate is N-
acetylated to form the molecule S-(3-oxopropyl)-N-acetylcysteine [25]. The aldehyde 
present on the molecule can then undergo reduction to form S-(3-hydroxy-propyl)-N-
acetylcysteine or oxidation to form S-carboxyethyl-N-acetylcysteine that is then excreted 
and detectable as acrolein metabolites in urine [26].  
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Detoxification of acrolein can also occur without the conjugation to proteins or 
antioxidants. Oxidation of acrolein by aldehyde dehydrogenase results in the generation 
of acrylic acid, 44-80% of which is metabolized to carbon dioxide as seen in studies 
using heavy acrylic acid administered to rats [12, 27, 28]. After acrolein binds to cysteine 
residues it can create cross-links with lysine by forming a schiff base with lysine’s ε-
amino group as described before. This is only an intermediate species that undergoes an 
electron shift rearrangement resulting in the regeneration of free cystenine thiol.  
In summary, studying the effects of acrolein on the lung epithelium will provide 
further insight into understanding the signaling mechanisms and hazards associated with 
CS exposure. Although there are thousands of chemicals present in CS, acrolein is shown 
to be a key mediator of many CS related outcomes and remains an important molecule of 
study. Further research is necessary to better understand how acrolein reacts with proteins 
and signaling pathways in the lung epithelium and how these alterations affect normal 
lung biology.  
1.3. Src 
The non-receptor tyrosine kinase Src is the prototypical member of the Src family 
kinases and is ubiquitously expressed in the body. Src was first discovered following 
research established by Peyton Rous, showing that a viral infection could produce tumors 
in chickens [29]. Identification of Src as the first proto-oncogene led to Nobel Prizes in 
1996 and 1989. Overexpression of Src is commonly observed in cancers with Src 
activation promoting increased cell migration, invasiveness, and epithelial remodeling 
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  There are nine different Src family kinases that share a conserved sequence 
homology consisting primarily of three different domains, those being an SH2 domain, an 
SH3 domain and a kinase domain. Src also contains a C-terminal regulatory tail domain 
and a unique SH4 domain at the N-terminus that includes a myristoyl group that can 
insert into the plasma membrane and assists in sub cellular localization [31]. Under basal 
conditions Src is held in an inactive conformation through interactions between its SH2 
domain and a phosphorylated tyrosine residue (Y527) on the C-terminal tail as well as 
interactions between its SH3 domain and a proline P-X-X-P consensus sequence found 
between the SH3 domain and the kinase domain [32]. These interactions maintain Src in 
a closed inactive conformation. Regulation of Src activity classically involves the 
dephosphorylation of Y527 that allows the protein to unfold and undergo a 
conformational change. Once open, Src autophosphorylates at Y416 further increasing 










kinase activity that can be detected by western blot as a measure of kinase activation [33]. 
Tyrosine Y416 is located on a flexible alpha-helix loop (A-loop) on the kinase domain 
and takes on an ordered conformation under basal conditions and adds to the negative 
regulation of Src activity by filling the catalytic cleft of the kinase domain restricting 
access to ATP and substrates [34].  
Viral Src (v-Src) was identified as the responsible factor present in the Raus 
sarcoma virus that let to its transforming ability. Sequence analysis revealed that v-Src 
differed from cellular Src in that it lacked the C-terminal regulatory tail domain 
containing Y527 [34]. Since a closed inactive conformation could not be maintained 
through binding interactions between the C-terminal tail and the SH2 domain, it was 
found that v-Src was constitutively active. As a result, cells containing v-Src show 
increased invasiveness, proliferation, and resistance to apoptosis [31].  
Phosphorylation of Src at Y527 is regulated through the dynamic activity between 
kinases and phosphatases. Phosphorylation is decreased by protein tyrosine phosphatases 
such as SHP1 and PTP1B, leading to a release of the SH2 domain and opening of the 
protein resulting in increased kinase activity. The catalytic site of PTP1B contains a 
redox sensitive cysteine residue and has been shown to be inactivated through oxidation 
or through adduction to acrolein [35]. Phosphorylation of Y527 is performed by Csk (c-
Src kinase) promoting the inactive closed form of Src. Additional regulation by Csk 
occurs through the protein Cbp (Csk binding protein), which is a transmembrane protein 
and recruits Csk to the membrane where Src is localized promoting their interaction and 
phosphorylation [36]. The only phosphatase known to remove phosphate from Y416 is 
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PTP-BAS [33]. Alteration of activity in these different kinases and phosphatases are 
commonly found in diseased states associated with altered Src activity [37].  
Recent studies have shown that Src can also be regulated through the oxidation of 
cysteine residues located throughout the protein. Src contains 9 cysteine residues, 3 in the 
SH2 domain and 6 in the kinase domain. Through the generation of mutant cell lines 
containing cysteine to alanine mutations, Giannoni et al. 2005 demonstrated that the 
oxidation of cysteine residues C245 and C487 are involved in an oxidant induced 
activation of kinase activity, and suggest the oxidation events result in the formation of 
an intramolecular disulfide bond [38]. The importance of cysteine oxidation in activation 
of kinase activity was further supported by Zhang et al. 2014, providing evidence of a 
redox based activation mechanism involving oxidation of cysteine residues C245, C277, 
and C501 in response to TGFβ1 [39]. Interestingly, contrasting evidence supports the 
inactivation of Src activity in response to oxidants. Kemble et al. 2008 showed that 
oxidation of C277 results in the formation of a Src dimer through an intermolecular 
disulfide bond that inactivates kinase activity [40]. In addition to activation by oxidation, 
Src can be activated by the lipid peroxidation product 4-Hydroxynonenal through the 
mediation of PTP1B, and EGFR signaling [41].  
Exposure to CS results in the activation of Src, however the exact activation 
mechanism remains unclear. Chronic cigarette smoke exposure causes remodeling of the 
lung epithelium with an increase in expression of MMP9, increased MAPK signaling and 
increased lung tissue destruction, mediated through activation of Src [42]. Additionally, 
features of EMT such as loss of E-cadherin, gain of vimentin and smooth muscle actin 
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occur through Src mediated pathways in response to CS exposure [43]. CS exposure 
weakens the lung epithelium through the disruption of cell contacts known as adherens 
junctions [44]. E-cadherin is the primary structural component of adherens junctions and 
links the cell membrane to the actin cytoskeleton. Src regulates the stability of E-cadherin 
through the phosphorylation of the adherens junction protein p120, where upon 
phosphorylation it dissociates from the adherens junction complex resulting in E-cadheirn 
endocytosis and degradation [45].  
Current research has established Src as a key protein that is activated in response 
to cigarette smoke, however the mechanism of activation remains uncertain. While 
oxidative signaling mechanisms have been proposed, we looked to determine the effects 
of acrolein on Src activation and how Src activation plays a role in the effects of acrolein 
on lung epithelial cells.   
1.4 Current Studies 
Our primary goal of this work was to assess Src activation in response to acrolein 
and the role of Src in acute and chronic acrolein exposure in the lung epithelium. We 
hypothesize that chronic acrolein exposure will result in features of EMT and lung 
remodeling similar to those observed by chronic cigarette smoke exposure. Additionally, 
we hypothesized that acrolein activates Src by directly modifying cysteine residues on the 
protein to promote an active conformation. To test our first hypothesis we measured the 
effects of acute and chronic acrolein exposure in mouse tracheal epithelial cells and in an 
in vivo mouse exposure model.  We utilized the Src inhibitors PP2 and AZD0530 to test 
to role of Src in these responses.  To test our second hypothesis we exposed H292 cells or 
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purified Src to acrolein and measured activation through detection of Src targets using 
western blot or an in vitro kinase activity assay. Additionally, we used biotin conjugated 
probes and mass spectrometry to identify cysteine modification in H292 cells and 
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CHAPTER 2: ACROLEIN REDUCES EPITHELIAL BARRIER FUNCTION 
THROURGH SRC ACTIVATION 
2.1. Abstract 
The lung epithelium provides the first line of defense against inhaled chemicals, 
pathogens, and particulate matter through the physical barrier it creates between the lung 
and the external environment. It has been observed that acute cigarette smoke exposure 
leads to a weakening of epithelial barrier function and a loss of adherens junction 
proteins, whereas chronic cigarette smoke exposure leads to tissue destruction and a 
phenomenon known as Epithelial to Mesenchymal Transition (EMT) through activation 
of the Src kinase. In the current studies we tested the effects of acrolein, a highly reactive 
chemical found in cigarette smoke, on the lung epithelium in both acute and chronic 
exposure settings and examined the role of Src activation in these responses. Acute 
acrolein exposure of mouse tracheal epithelial cells (MTECs) resulted in a dose 
dependent decrease in barrier resistance measured by trans epithelial resistance (TER) 
and a subsequent increase in epithelial permeability to FITC-dextran. Pretreatment with 
the Src inhibitor PP2 prevented loss of epithelial barrier function. Further analysis of 
protein by western blot revealed a dose dependent loss of junction proteins E-cadherin 
and ZO-1, which was prevented with Src inhibition. Using confocal microscopy we show 
that E-cadherin is lost from the cell membrane while simultaneous studies using biotin 
conjugated probes show a loss of E-cadherin surface labeling following acrolein 
exposure. Preliminary studies show that acute acrolein exposure of C57BL/6 mice (5 
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ppm for 4 hrs) resulted in increased airway epithelial permeability that could be 
attenuated using the Src inhibitor AZD0530.  Together these studies show that acrolein 
exposure causes a weakening of the epithelial through loss of E-cadherin in a Src 





Chronic obstructive pulmonary disease (COPD) is a group of diseases 
characterized by an irreversible restriction of airflow in the lung and includes the 
disorders emphysema and chronic bronchitis. COPD differs from asthma in that 
inflammation and restriction of airways is not reversible. In patients with COPD, chronic 
inflammation, fibrosis and mucus secretion leads to a destruction of lung tissue and loss 
of lung function [46]. Smoking cigarettes is one of the greatest risk factors for the 
development of COPD with over half of COPD patients being smokers [1]. It’s been 
shown that reactive oxygen species (ROS) generated in CS contribute to the development 
of COPD by increasing activation of the non-receptor tyrosine kinase Src and Epidermal 
Growth Factor Receptor (EGFR) partially through MAPK signaling leading to epithelial 
injury [6]. Activation of Src has largely been studied as a contributing factor in the 
development of cancer, being the first characterized oncogene contributing to increased 
cell migration, proliferation, and invasion, although increasing evidence suggests these 
properties of Src activation are also involved in the development of COPD [6, 31]. 
Stability of the adherens junction protein E-cadherin is regulated by Src activation and is 
decreased in response to CS leading to weakened epithelial barrier function, which is a 
feature of COPD [44, 47]. The alpha beta unsaturated aldehyde acrolein is present in 
cigarette smoke at levels as high as 90 ppm and has been shown to cause many of the 
negative effects of CS [13].  
The lung epithelium protects the body from inhaled particulate matter, pathogens 
and environmental pollutants by providing a physical barrier that is maintained through 
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cell-to-cell connections known tight junctions and adherens junctions [48]. The adherens 
junction is made up of a complex of proteins including E-cadherin, alpha catenin, beta 
catenin, and delta catenin also known as p120. E-cadherin is a transmembrane protein 
that forms the connection to neighboring cells through its extracellular Ca+ binding 
domain while its intracellular domain links the cell membrane to the actin cytoskeleton 
through alpha and beta catenin and p120 [49]. p120 stabilizes the adherens junction 
through binding to E-cadherin and is a phosphorylation target of Src [50]. Upon 
phosphorylation of tyrosine Y228, p120 dissociates from the adherens junction increasing 
E-cadherin endocytosis and degradation. Additionally p120 expression is observed to be 
decreased or absent in a number of cancers suggesting that the association of p120 with 
E-cadherin could act as a tumor suppressor by maintaining a proper epithelial cell like 
phenotype [51].  
Loss of E-cadherin is commonly associated with the development and progression 
of cancer involving a process known as epithelial to mesenchymal transition (EMT). 
Epithelial to mesenchymal transition (EMT) is a process in which epithelial cells lose 
their epithelial phenotype and gain a more mesenchymal phenotype including enhanced 
cell migration, invasiveness, and increased metastatic potential [52]. One of the hallmark 
characteristics of EMT is the loss of epithelial cell markers E-cadherin and a gain of 
mesenchymal gene expression of proteins such as vimentin, fibronectin, and smooth 
muscle actin.  Previous research has shown that chronic cigarette smoke exposure results 
in the development of EMT through the activation of Src [42, 43]. In the current studies 
we examined the effects of chronic acrolein exposure on the lung epithelium to see if 
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acrolein could mimic the effects of chronic CS exposure such as a loss of E-cadherin, 
increased collagen deposition, and other features of EMT.   
We tested the effects of acute and chronic acrolein exposure on the lung 
epithelium in both in vitro and in vivo models and studied how Src activation regulates 
airway epithelial injury and barrier integrity through control of E-cadherin stability and 
endocytosis. We hypothesized that acute acrolein exposure causes lung epithelial damage 
through Src activation while chronic acrolein exposure leads to lung remodeling events 
similar to those following chronic cigarette smoke exposure. Our findings demonstrate 
that acrolein reduces epithelial barrier integrity that can be prevented through Src 
inhibition. We show that this process occurs through the activation of Src and subsequent 





2.3.1. Cell Culture  
NCI-H292 cells (ATCC) were cultured in RPMI-1640 (Gibco) media 
supplemented with 10% FBS and 1% Penicillin/Streptomycin (Gibco). Primary mouse 
tracheal epithelial cells (MTECs) were isolated from C57BL/6J mice (Charles River) as 
previously described by Wu and Smith [53]. MTECs were grown in DMEM/F12 media 
supplemented with 20 ng/mL cholera toxin (List Biological Laboratories; Campbell, CA), 
5 µg/mL insulin (Sigma), 5 µg/mL transferrin (Sigma), 15 µg/mL bovine pituitary extract 
(Invitrogen), 10 ng/mL EGF  (Calbiochem; San Diego, CA), 100 nM dexamethasone 
(Sigma), 2 mM L-glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin. Cells were 
grown in a 5% CO2 environment at 37°C.   
2.3.2. Cell Treatments 
Cells were starved in serum free media without phenol red for 24 hours prior to 
experimentation. Starvation media was replaced at least one hour prior to experiment. 
Acrolein (Sigma) was diluted in H2O to a working concentration of 10 mM then added to 
media for final concentrations ranging from 1-100 µM. Inhibitors PP2 and AZD0530 
(Saracatinib) were reconstituted in DMSO for a stock solution of 10 mM then diluted in 
serum free media without phenol red to a concentration of 10 µM PP2 or 1 µM 
AZD0530. Cells were incubated with inhibitors for 30 min prior to experiment. For 
chronic acrolein exposure in MTECs, cells were treated with 3, 10, or 30 µM acrolein 
every day, while media was changed every other day. Following acrolein treatment, cells 
were washed once with cold PBS before being lysed. To collect protein cells were lysed 
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on ice for 30 minutes in Western Solubilization Buffer (WSB) containing 1% Triton, 50 
mM HEPES, 250 mM NaCl, 10% Glycerol, 1.5 mM MgCl2, 1 mM PMSF, 1 mM EGTA, 
2 mM Na3VO4, 10 µg/ml Aprotinin, 10 µg/ml Leupeptin. Protein levels were determined 
using a bicinchoninic acid (BCA) protein assay (Pierce). To collect RNA cells were lysed 
in buffer supplied by the Gene Jet RNA Purification Kit (Thermo) following the 
manufacturers protocol. 
2.3.3. MTEC permeability assay  
MTECs were seeded at 200,000 cells/well in 12-well Transwell® inserts 
(Corning) that were coated in 50 µg/ml rat tail collagen-1, and cultured in full media as 
previously described. Cells were grown until tight junctions had formed, which was 
determined by a plateau in trans-epithelial resistance (TER) measured by a volt-ohm 
meter (World Precision Instruments).  Prior to acrolein exposure, designated cells were 
treated apically with 10 µM PP2 in full media. Acrolein was prepared as previously 
described and added to inserts at final concentrations of 30 and 100 µM. TER was 
measured over the course of 24 hours at which point apical media was removed and 
replaced with phenol free media containing 5 mg/mL FITC-Dextran (Sigma, molecular 
weight 4kDa). After an additional 24 hours fluorescence of basal media was measured 
(excitation 492 nm; emission 520 nm) using a Biotek Synergy HT plate reader (BioTek). 
Cells were then washed twice with cold PBS and lysed with Western Solubilization 
Buffer (WSB) for protein analysis.   
2.3.4. Western blot 
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Equal amounts of protein were loaded in 10% tris-glycine SDS-PAGE gels 
(BioRad), separated and transferred to a nitrocellulose membrane (Thermo), and blocked 
in 5% non-fat milk.  Primary antibodies for Src, pSrc-Y416, E-cadherin, p120, pp120-
Y936, were supplied by Cell Signaling Technologies and used at a dilution of 1:1000 in 
5% BSA in tris-buffered saline plus 0.1% Tween® 20 (TBS-T). Beta-actin (Sigma) was 
used at a dilution of 1:10,000 in TBS-T 5% BSA. Membranes were incubated with 
secondary HRP conjugated rabbit and mouse antibodies (Cell Signaling) at a dilution of 
1:1000 in 5% milk in TBS-T. Proteins were detected with enhanced chemiluminescent 
substrate (Pierce) and x-ray film (Kodak) or the Amersham™ Imager 600 (GE Life 
Sciences).  
2.3.5. In vivo acrolein exposure   
For an acute acrolein exposure in vivo, C57BL/6 mice (Charles River) were 
exposed to 5 ppm acrolein (Sigma) vapor at a flow rate of 2.5 L/min for 4 hours in a glass 
exposure chamber. Acrolein concentration was monitored by a Miran SapphIRe air 
analyzer (Thermo Scientific). Immediately after acute exposure, mice were sacrificed to 
harvest lung tissue for protein and RNA analysis. Mice were also submitted to a chronic 
exposure of 5 ppm acrolein for 4 hours, 5 days/week for 2 weeks. In the chronic exposure 
model, mice were sacrificed 3 days after the last acrolein exposure to harvest 
bronchoalveolar lavage fluid (BALF), protein and RNA. After trachea cannulation, lungs 
were washed three times using 500 µL sterile PBS as room temperature. After spinning at 
1,500 rpm for 5 min to pellet cells, lavage fluid was removed for analysis by ELISA, 
while the cell pellet was resuspended in 500 µL PBS and split for analysis by an ADVIA 
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hematology system (Siemens) (200 µL) and cytospin (300 µL). Cytospin slides were 
stained with hematoxylin and eosin.  
2.3.6. FITC-dextran injections  
Prior to acrolein exposure mice were given vehicle (PBS) or the Src inhibitor 
AZD0530 at a concentration of 50 nM in 50 µL through nasal instillation.  Mice were 
then injected with 25 mg/mL FITC-Dextran in the tail vein and exposed to 5 ppm 
acrolein for 4 hours. BALF was collected by lung lavage two times with 500 µL PBS at 
room temperature. Blood was collected with a pipette after severing the carotid artery and 
spun down at 8,000 rpm in serum collection tubes (BD Microtainer). BALF and serum 
fluorescence was measured (excitation 492 nm; emission 520 nm) using a Biotek 
Synergy HT plate reader (BioTek). Epithelial permeability was measured as the ratio of 
BALF to serum fluorescence.  
2.3.7. Confocal Microscopy 
H292 cells were seeded in glass chamber slides (Millipore) and grown until >90% 
confluent. Acrolein (Sigma) was prepared as described above and added to wells at a 
concentration of 100 µM for 3 hours. Cells were washed once with cold PBS then fixed 
with 4% paraformaldehyde (PFA) in 1% bovine serum albumin (BSA) for 1 hour. Cells 
were permeabilized with 0.2% TritonX100 in 1% BSA for 15 min then blocked with 10% 
goat serum for 1 hour. Cells were stained with an E-cadherin rabbit primary antibody 
(1:250) and secondary goat anti-rabbit Alexa-555 conjugated IgG (1:500). Cell nuclei 
were stained with 10 µg/mL DAPI, and then imaged using a Zeiss LSM confocal 





H292 cells were transfected at 50% confluence in serum free media using 
SMARTpool Src siRNA (Dharmacon) and DharmaFECT™ transfection reagent 
(Dharmacon) overnight. Transfected cells were then grown in serum containing media for 
24 hours followed by starvation and experimentation.  
2.3.9. PCR 
RNA was isolated from cell lysates or mouse lung homogenates using the 
GeneJET RNA purification kit (Thermo) as directed by the manufacturer and quantified 
using a Biotek plate reader. cDNA was generated using Oligo(dT) 12-16 primer 
(Promega), dNTPs (Invitrogen) and M-MLV reverse transcriptase (Invitrogen). qRT-PCR 
was performed using SYBR Green Supermix (BioRad) and normalized to GAPDH.  
Primer Sequences: 
Gene Forward Reverse 
GAPDH CTGGAGAAACCTGCCAAGTA TGTTGCTGTAGCCGTATTCA 
HO-1 AAGACTGCGTTCCTGGTCAAC AAAGCCCTACAGCAACTGTCG 
E-cadherin TCTTGGCGTTTCTTTCAAAC CAAAGATTCCAGCCAGAAAA  
Vimentin TCCAAGTTTGCTGACCTCTC CTCTTCCATCTCACGCATCT 
TGFB1 TGCTTTAGCTCCACAGAGAA TGGTTGTAGAGGGCAAGGAC 
MMP9 CTCACTCACTGTGGTTGCTG TGGTTATCCTTCCTGGATCA  






Muc5B CCTCTCCTGTCCACCCACTA TCCATGCGTGAGTTGAAGAG 
CCL20 CGTCTGCTCTTCCTTGCTTT TTGACAAGTCCACTGGGACA 
2.3.11. Biotinylation 
To label E-cadherin at the cell surface following acrolein treatment, H292 cells 
were incubated with 100 µM EZ-Link™ NHS-Biotin for 1 hour to label all surface 
proteins, washed 2x with PBS then lysed with WSB. To label endocytosed E-cadherin 
H292 cells were labeled with 0.5 mg/mL EZ-Link™ NHS-SS-Biotin prior to acrolein 
treatment for 1 hour. Cells were washed 2x with PBS then treated with 100 µM acrolein 
for 3 hours. Following acrolein exposure cells were washed with cold PBS then incubated 
with 100 µM GSH on ice to cleave the biotin tag from proteins remaining at the cell 
surface. Cells were then lysed on ice with WSB, scraped and sonicated. After quantifying 
protein using a bicinchoninic acid (BCA) protein assay (Pierce), an equal amount of 
protein from each sample was washed 5x with 20 mM Tris pH 7.4 in an Amicon® Ultra 
3k centrifugal spin column (Millipore) to remove excess biotin. Washed protein was 
brought to a volume of 500 µL using WSB and added to high capacity NeutrAvadin™ 
agarose beads (Thermo) to isolate biotinylated proteins. Beads were incubated at 4°C 
overnight then washed as previously described [54].  Eluted protein was mixed with 
6xRSB then separated on SDS-PAGE for western blot.  
2.3.12 Statistical analysis 
Data was represented as the mean +/- SEM. Statistical significance was determined by t-
test or ANOVA when more than two groups were present. Significance was set at a 




2.4.1. Acute acrolein exposure reduces lung epithelial barrier function through Src 
activation. 
 Since Src is known to regulate the stability and expression of the adherens 
junction protein E-cadherin and cigarette smoke reduces epithelial barrier integrity we 
analyzed the effects of Src activation on the lung epithelium following acrolein exposure. 
We grew mouse tracheal epithelial cells in Transwell® cell culture plates and used two 
different methods to determine the effects of acrolein on lung epithelial barrier function. 
We measured the trans epithelial resistance (TER) of an epithelial monolayer using a 
volt-ohm meter and measured physical permeability of a cell monolayer using FITC-
dextran. We observed a decrease in TER over time after treatment with 30 µM and 100 
µM acrolein indicating a weakening of the epithelium (Fig 2.1A). After 24 hours apical 
cell media was replaced and supplemented with cell media containing 5 mg/mL FITC-
dextran. We saw an increase in the permeability of cells treated with acrolein measured 
by an increase in FITC-dextran in basal media (Fig. 2.1B). When we analyzed protein by 
western blot we observed a reduction in the presence of E-cadherin and ZO-1 in acrolein 
treated cells consistent with results indicating loss of epithelial barrier integrity (Fig. 
2.1C). To determine the role of Src on epithelial barrier function we inhibited Src activity 
using the pharmacological inhibitor PP2. Pretreatment with 10 µM PP2 completely 
prevented the loss of TER, permeability to FITC-dextran and loss of E-cadherin and ZO-
1 following acrolein exposure, suggesting that Src activation is playing an important role 
in regulating epithelial barrier function (Fig 2.1). 
27 
 
 After loss of epithelial barrier function was confirmed using in vitro models, we 
measured the effects of acrolein on lung epithelial permeability in vivo. Mice were 
injected with 25 mg/mL FITC-dextran in the tail vein then exposed to 5 ppm acrolein for 
4 hours. The ratio of FITC fluorescence in the BALF normalized to the FITC present in 
the blood serum was used as a measure of epithelial barrier integrity. When BALF and 
serum was analyzed there was a modest yet significant increase in FITC fluorescence in 
acrolein exposed mice (Fig 2.2). Mice treated intranasally with the Src inhibitor 
AZD0530 before acrolein exposure showed a significant reduction in epithelial 
permeability compared to PBS controls demonstrating that Src inhibition prevents 
weakening of epithelial barrier integrity when exposed to acrolein (Fig 2.2).   
2.4.2. Acrolein induces a redistribution of E-cadherin  
We next looked to determine the effects of acrolein on E-cadherin visually using 
confocal microscopy. H292 cells were grown in chamber slides and transfected with non-
specific (NS) siRNA or Src siRNA to silence Src expression. After treatment with 
acrolein for 4 hours we saw a reduction in E-cadherin fluorescence in NS-siRNA cells 
and no loss of E-cadherin in cells transfected with Src siRNA (Fig 2.3A). To analyze the 
levels of E-cadherin present after acrolein treatment we performed an experiment under 
similar conditions and lysed cells to analyze protein content by western blot. 
Interestingly, in the acrolein treated cells there was no significant reduction in E-cadherin 
at similar concentrations and time points compared to the levels measured by confocal 
microscopy (Fig 2.3B).   
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We hypothesized that acrolein was inducing E-cadherin endocytosis removing it 
from the cell membrane, resulting in reduced E-cadherin intensity at the membrane while 
total proteins levels remains the same. To test this hypothesis, we used two membrane 
impermeable probes to label E-cadherin at the cell surface and track its localization 
following acrolein treatment. Following acrolein treatment of H292 cells and labeling 
surface proteins with EZ-Link™ Sulfo-NHS-Biotin, E-cadherin was isolated from cell 
lysates using NeutrAvadin agarose beads. We observed a reduction in isolated E-cadherin 
after acrolein treatment while there was no change in E-cadherin levels in whole cell 
lysates indicating that E-cadherin endocytosis had occurred (Fig 2.4). Although we were 
able to prevent loss of E-cadherin through Src siRNA transfection as analyzed by E-
cadherin immunofluorescence imaging (Fig 2.3A), we were not able to prevent loss of E-
cadherin surface labeling through the use of Src siRNA (Fig 2.4). As an alternative 
labeling strategy, we utilized a biotin tag that could be cleaved off using a reducing agent. 
By labeling surface proteins and allowing for endocytosis, cleaving the label with a 
membrane impermeable reducing agent results in labeling of only endocytosed proteins 
that could then be purified by avadin chromatography. After performing this experiment 
and analyzing labeled proteins by western blot we did not observe any differences in E-
cadherin between untreated and acrolein treated H292 cells. Since the biotin tag was 
cleaved from surface proteins this indicates that endocytosis is occurring in both 





2.4.3. Chronic acrolein exposure results in loss of E-cadherin in vitro.  
 Previous reports indicate that cigarette smoke exposure results in the development 
of EMT through the activation of Src. To determine if chronic acrolein exposure resulted 
in features of EMT in vitro, we exposed mouse tracheal epithelial cells (MTECs) to 
acrolein every day for two weeks. After two weeks cells were lysed and analyzed by 
western blot and qRT-PCR to determine the presence of any epithelial alterations. qRT-
PCR analysis shows an increasing trend of vimentin and Col1A1 in cells treated with 30 
µM acrolein (Fig 2.5A). We did not observe any changes in expression of E-cadherin or 
TGFB1. Analysis by western blot shows a reduction of E-cadherin after chronic exposure 
to 30 µM acrolein (Fig 2.5B).  
We next tested the effects of chronic acrolein exposure in vivo by exposing mice 
to 5ppm acrolein for 4 hours a day for 2 weeks. Preliminary experiments conducted in the 
laboratory had shown that chronic acrolein resulted in decreased of E-cadherin, increased 
vimentin and increased in Src phosphorylation detected by western blot. Additionally, we 
observed increased TGF-β1 expression and release detected by PCR and ELISA 
respectively (O’Brien et al, unpublished data). After mice were exposed to 5 ppm 
acrolein for 4 hours a day for 2 weeks a panel of genes involved in EMT and epithelial 
alterations was examined by qRT-PCR and western blot. We observed an increase in 
MMP9 and the neutrophil chemoattractant KC (Fig 2.6A) and upward trends of Muc5b 
and CCL20. We did not observe any differences in BALF cell count or Masson’s 
Trichrome (Fig 2.6B and C). Lastly, we did not observe any differences in protein levels 




 Exposure to cigarette smoke is associated with an increased risk in the 
development of COPD and lung cancer. Increasing evidence supports the role of reactive 
oxygen species in these processes leading to DNA damage, increased inflammation, and 
altered signaling activity both activating and inhibitory through binding to redox sensitive 
cysteine thiols [38, 40]. Studies have demonstrated that Src activation by cigarette smoke 
is responsible for lung tissue destruction, a loss of E-cadherin and a reduction in 
epithelial barrier integrity [42]. We hypothesized that reactive aldehydes could induce Src 
activation leading to similar changes in the lung epithelium. Indeed, we show that 
acrolein reduces epithelial barrier function through activation of Src as seen in 
experiments using MTECs (Fig 2.1).  Further we show evidence that acrolein incudes E-
cadherin endocytosis as an early step in protein degradation (Fig 2.4).  
Work by Zhang et al. 2012 established that cigarette smoke exposure led to the 
development of EMT through activation of Src [43]. While this work highlighted the 
importance of Src in the overall development of EMT, they did little to show a 
mechanism how this response was occurring. Our work looks deeper into the mechanism 
of how cigarette smoke leads to activation of Src, and the effects of active Src on 
epithelial function. We show evidence that acrolein activates Src and leads to the 
phosphorylation of p120, which is involved in stability of the adherens junction complex 
[50]. Following phosphorylation p120 dissociates from the adherens junction complex 
leading to complex instability and subsequent endocytosis [45]. It is likely that the 
reduction in barrier function we observe in MTECs is a result of p120 phosphorylation 
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and degradation of E-cadherin.  Further, we show an increase in MMP9 and KC 
following chronic acrolein exposure in mice (Fig 2.6A) that is consistent with findings by 
Geraghty et al. 2014 showing these effects in response to chronic CS exposure [42].  
 The development of COPD and lung cancer is a gradual process that occurs over 
time. Similarly, EMT is not a rapid process and will not occur after a single dose of CS or 
acrolein. Although loss E-cadherin is known to induce EMT, it is too early to consider 
our observations EMT. In our chronic MTEC exposure model we see a loss of E-cadherin 
without any changes in E-cadherin gene expression. When E-cadherin is endocytosed 
from the cell surface, the adherens junction complex of proteins dissembles and no longer 
binds to β-catenin, which can act as a transcription factor in the nucleus [55]. This would 
suggest that E-cadherin protein loss would precede alterations in mRNA expression and 
loss of gene expression may occur due to secondary effects of β-catenin signaling in the 
Wnt pathway. We cannot assume our results are a direct observation of EMT, however 
they could be early signaling events that lead to lung epithelial remodeling. An important 
consideration to make in the interpretation of these studies is that acrolein is influencing 
numerous signaling pathways in the cell [9], therefore it would be naïve to think that all 
of the effects we observe are attributed solely to Src activation. 
 Together these studies demonstrate that acrolein exposure causes a weakening of 
epithelial barrier function and that Src plays a central role in this process. We observed 
what might be considered early events in epithelial remodeling in our chronic MTEC 
exposure model after two weeks of acrolein exposure, supporting our hypothesis that 
acrolein induces similar changes to the lung epithelium as chronic CS exposure, however 
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future studies are necessary to strengthen these claims. The effects of reactive aldehydes 
on the development of lung disease will continue to be an area of interest in future 
research helping better understand mechanisms of signaling events in response to 


















Figure 2.1. Inhibition of Src prevents loss of epithelial barrier function following 
acrolein exposure. MTECs were grown in Transwell® cell culture plates, pretreated 
with 10 µM of the Src inhibitor PP2 for 30 min then exposed to acrolein. Trans epithelial 
resistance (TER) was measured over 24 hours (A) *p<0.05 n=4. Permeability to the 
fluorescent molecule FITC-Dextran was measured after incubation on cells for 24 hours 
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Figure 2.2. Acute acrolein exposure decreases lung epithelial barrier function in 
vivo. Mice were given AZD0530 through nasal installation at a concentration of 50 nM in 
50 µL. Mice were then injected with 5 mg/mL FITC-Dextran in the tail vein and exposed 
to 5 ppm acrolein for 4 hours.  Serum and BALF was collected and analyzed for the 




























Air PBS mean = 100
Air AZD mean = 102.38
ACR PBS ean = 116.37


















Figure 2.3. Src knockdown by siRNA prevents loss of E-cadherin at the cell 
membrane. H292 cells were grown in chamber slides until 50% confluent then 
transfected with non-specific or Src siRNA. Cells were then treated with 100 µM acrolein 
for 3 hours and fixed for immunofluorescent imaging by confocal microscopy. 
Blue=DAPI, Red=E-cadherin, Bar = 100 µm (A). H292 cells were grown in 24 well 
plates then exposed to 100 µM acrolein for 3 hours. Cells were lysed and analyzed for E-




















Figure 2.4. Acrolein exposure reduces E-cadherin surface labeling. H292 cells were 
transfected with Src siRNA then exposed to 30 µM acrolein for 3 hours. Surface proteins 
were labeled with EZ-link Sulfo-NHS-Biotin then isolated with NeutrAvadin beads. 

















































Figure 2.5. Chronic acrolein exposure in MTECs. MTECs were grown to confluence 
and exposed to 3, 10 or 30 µM acrolein daily for 2 weeks. Protein and RNA was 


























































































































































































































Figure 2.6. Chronic acrolein exposure in vivo. C57BL/6 mice from Jackson Labs were 
exposed to 5 ppm acrolein daily for two weeks. RNA was isolated from whole lung tissue 
homogenates and analyzed by PRC and normalized to GAPDH (A) (Air n=6, ACR n=8 ) 
*p<0.05.  BALF was spun at 1,500 rpm for 5 min to collect cells. Pellet was resuspended 
in 500 µL PBS and counted by ADVIA® hematology system (Siemens) (B). Mouse 
lungs were fixed in 4% paraformaldehyde and sectioned for histology. Lung sections 
were stained with Masson’s Trichrome and imaged on a bright field microscope at 4x 
magnification. Representative images shown (C). Protein was isolated from whole lung 


















Figure 2S1. Alterations in internalized E-cadherin are not detected following 
acrolein treatment. H292 cells were labeled with a cleavable biotin tag then exposed to 
30 or 100 µM acrolein for 3 hours to allow for protein endocytosis. Biotin remaining at 
the membrane surface was cleaved by incubation with GSH. Endocytosed proteins were 
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CHAPTER 3: ACROLEIN BINDS TO SRC AND INDUCES KINASE 
ACTIVATION 
3.1. Abstract 
Many of the adverse effects of cigarette smoke can be attributed to the presence of 
reactive electrophiles such as the α,β-unsaturated aldehyde acrolein, which affects 
biological systems by primarily reacting with redox-sensitive cysteine residues. In the 
present studies we examined the effects of acrolein on lung epithelial cells and the 
importance of the redox-sensitive tyrosine kinase Src in these responses. Through the use 
of cell based models and recombinant Src in a cell-free system we were able to provide 
evidence supporting an aldehyde based signaling mechanism through direct acrolein 
adduction to redox sensitive amino acids. Acrolein exposure of H292 cells resulted in an 
increase in Src activation detected through phosphorylation of Y416 independent of 
Y527 dephosphorylation, which is consistent with a proposed non-canonical redox-based 
activation mechanism. Pretreatment with the Src inhibitor AZD0530 prevented Src 
phosphorylation and inhibited phosphorylation of downstream proteins p120 catenin and 
caveolin-1. Additionally, exposure of recombinant purified Src to acrolein resulted in an 
increase in kinase activity independent of tyrosine phosphorylation in a cell free system. 
Biochemical labeling approaches with aldehyde-reactive biotin tags revealed that Src is a 
direct target for acrolein-induced Michael adduction both in vitro and in vivo. Further 
studies utilizing mass spectrometry confirmed acrolein adduction to various cysteine 
residues including C245, C277 and C487, which have been implicated in redox-
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dependent activation of Src. This work indicates that acrolein directly binds to Src and 
that acrolein exposure results in an increase in Src activity potentially through a 






The α,β-unsaturated aldehyde acrolein is a highly reactive electrophile produced 
through the incomplete combustion of organic matter including CS, car exhaust, and coal 
burning power plants. Many of the adverse effects of CS can be attributed to reactive 
electrophiles such as acrolein through the generation of oxidative stress and depletion of 
antioxidants in the lung such as GSH [8], while past research has highlighted the 
importance of oxidative stress associated with CS exposure as a contributing factor in the 
development of COPD and lung cancer [6, 56, 57]. Although thiol based antioxidants 
such as GSH and NAC have been shown to block CS induced damage to the lung, 
suggesting an oxidative mechanism, analysis of GSH following CS exposure revealed the 
primary adduct to glutathione was acrolein, not oxidized GSH (GSSG), suggesting the 
protective role of antioxidants comes from detoxification of acrolein [8, 57]. Acrolein is 
classified as a soft electrophile that reacts primarily with soft nucleophiles through 
Michael addition to cysteine, lysine and histidine residues, and has been identified as the 
most abundant non-cancerous hazard present in CS [11, 58]. Acrolein’s reactivity with 
cysteine residues is of particular importance because many redox sensitive proteins 
contain cysteine residues. Previous work in the laboratory has shown that acrolein 
inhibits LPS-induced macrophage responses [16], inhibits NF-κB activation [59], and can 
activate MAPK signaling through alkylation of thioredoxin reductase 1 (TrxR1) [60].  
The current studies presented here examined the effects of acrolein on its ability 
to activate the non-receptor tyrosine kinase Src kinase in an effort to better understand the 
underlying mechanism of activation upon exposure to CS. Activation of Src plays a key 
46 
 
role in cell adhesion, motility, and proliferation although its mechanism of activation 
remains unclear [31]. It’s been shown that CS exposure activates Src and leads to tissue 
destruction and features of epithelial to mesenchymal transition [42, 43]. Several 
different activation mechanisms have been proposed involving the phosphorylation and 
dephosphorylation of tyrosine residues, modification by electrophiles such as 
hydroquinone, and the oxidation of several cysteine residues on the protein [38, 39, 61]. 
Oxidative modification of Src and other receptor tyrosine kinases such as EGFR has 
recently been highlighted as an important process mediating kinase signaling [62, 63]. 
The effects of CS have largely been attributed to reactive oxygen species and oxidative 
stress within the cell resulting in increased mucous metaplasia, disruption of epithelial 
junction proteins, and tissue destruction, all of which are all processes involving Src 
kinase activation and are associated with the development of COPD [6, 42, 64].  
Since CS exposure results in the activation of Src and previous studies have 
shown modification of cysteine residues are involved in kinase activation, the present 
studies were designed to assess the ability of acrolein to activate the non-receptor 
tyrosine kinase Src. We hypothesized that acrolein directly activates Src by binding to 
redox sensitive cysteine residues promoting an open active conformation. To test our 
hypothesis we characterized the effects of acrolein on Src activation through the use of 
cell culture models and recombinant protein kinase assays. We tracked the alkylation and 
oxidation of Src using biotin-conjugated probes and mass spectrometry to identify 
specific modified cysteine residues. Our studies confirmed that acrolein binds directly to 
Src and leads to increased kinase activity, as measured by a kinase activity assay and by 
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the phosphorylation of downstream Src targets. Together, this work emphasizes the 
importance of reactive aldehydes as signaling molecules found in CS and also provides 
further insight into understanding the activation mechanism of Src. These studies provide 
a better understanding of the signaling events that occur upon CS exposure that 
contribute to the development of lung disease and could offer insight into targets for 





3.3.1. Cell Culture  
Human pulmonary mucoepidermoid carcinoma NCI-H292 cells (ATCC) were 
maintained in RPMI-1640 (Gibco) media containing 1% Penicillin/Streptomycin and 
10% FBS (Gibco). Primary mouse tracheal epithelial cells (MTECs) were isolated as 
previously described by Wu and Smith [53] from C57BL/6J mice (Charles River). 
MTECs and human bronchial epithelial (HBEs) cells were cultured in DMEM/F12 media 
containing 20 ng/mL cholera toxin (List Biological Laboratories; Campbell, CA), 5 
µg/mL insulin (Sigma), 5 µg/mL transferrin (Sigma), 15 µg/mL bovine pituitary extract 
(Invitrogen), 10 ng/mL EGF  (Calbiochem; San Diego, CA), 100 nM dexamethasone 
(Sigma), 2 mM L-glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin. All cells 
were incubated at 37°C and 5% CO2.  
3.3.2. Cell Treatments 
To starve cells, at least 24 hours before experiments began, growth media was 
replaced with serum-free media without phenol red. One hour before experiments began 
starvation media was replaced with fresh serum free media. A working stock of acrolein 
(Sigma) was made in H2O at a concentration of 10 mM. Acrolein was added directly to 
cell culture media for desired final concentrations of 1-100 µM. Src inhibitors were 
prepared in DMSO as stock solutions of 10 mM. Inhibitors PP2 and AZD0530 were 
diluted to final concentrations of 10 µM and 1 µM respectively in serum free media 
without phenol red. Inhibitors were incubated on cells for 30 min prior to experiments. 
Prior to lysis, cells were washed with cold PBS then lysed for 30 min on ice using 
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Western Solubilization Buffer (WSB) containing 1% Triton, 50mM HEPES, 250 mM 
NaCl, 10% Glycerol, 1.5mM MgCl2, 1 mM PMSF, 1 mM EGTA, 2 mM Na3VO4, 10 
µg/ml Aprotinin, 10 µg/ml Leupeptin. Protein levels in cell lysates were quantified with a 
bicinchoninic acid (BCA) protein assay (Pierce). 
3.3.3. Western blot 
Cell lysates containing equivalent amounts of protein were separated on 10% tris-
glycine SDS PAGE gels (Biorad) and transferred to a nitrocellulose membrane (Thermo). 
Membranes were blocked in 5% non-fat milk for 1 hour.  Antibodies were supplied by 
Cell Signaling Technologies unless otherwise noted. Primary antibodies for E-cadherin, 
vimentin and ZO-1 (Invitrogen), were diluted 1:1000 in Tris-buffered saline containing 
5% BSA and 0.1% Tween® 20 (TBS-T). Beta-actin antibody (Sigma) was diluted 
1:10,000 in 5% BSA TBS-T. Secondary antibodies (Cell Signaling) were diluted 1:1000 
in 5% milk in TBS-T and incubated on membranes for 1 hour at room temperature. 
Membranes were incubated for 5 min with enhanced chemiluminescent substrate (Pierce) 
to identify proteins by x-ray film (Kodak) or Amersham™ Imager 600 (GE Life 
Sciences).  
3.3.4. Mouse Lung Section Immunofluorescence 
After an acute acrolein exposure (5 ppm for 4 hours) as previously described in 
Chapter 2, mouse lungs were removed and fixed in 4% PFA before being embedded in 
paraffin. Embedded lung tissue was sectioned and stained with HO-1 rabbit primary 
antibody (1:250) and secondary goat anti-rabbit Alexa-555 conjugated IgG (1:500). Cell 
nuclei were stained with 10 µg/mL DAPI then imaged as described above.  
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3.3.5. Src activity Assay 
Src activity was determined with the Antibody Beacon™ Tyrosine Kinase Assay 
kit (Invitrogen) using 1.5 ng recombinant Src (Millipore T413M) or immunoprecipitated 
Src from H292 cells diluted in 25 µL kinase buffer. Kinase assay components were added 
together in a 96 well plate as described in the protocol. Src was added to wells containing 
kinase assay components and incubated at 37°C for 2 hours. The kinase assay kit contains 
an antibody that binds and quenches a fluorophore that can be displaced by a 
phosphorylated synthetic peptide. Increased kinase activity produces more 
phosphorylated peptide leading to an increase in fluorescence that can be measured by a 
plate reader (BioTek) at Ex/Em 492/517 nm. 
3.3.6. Biotinylation 
To label acrolein adducts, biotin-hydrazide (Pierce) was prepared in DMSO as a 
50 µM stock. Equal amounts of cell lysates were reacted with biotin-hydrazide at a final 
concentration of 5 µM for 2 hours at room temperature. An equal volume of 20 µM 
sodium cyanoborohydride was reacted with each sample on ice for 1 hour to reduce and 
stabilize the hydrazine bond. DCP-Bio1 (Kerafast) was added to WSB at a final 
concentration of 1 mM to label sulfenic acids. Lysis buffer was supplemented with 200 
U/mL catalase to remove hydrogen peroxide and 10 mM N-Ethylmaleimide to alkylate 
free cysteine thiols to prevent further oxidation. Cells were lysed on ice for 1 hour then 
scraped and sonicated.  Free cysteine thiols were labeled using WSB supplemented with 
100 µM EZ-Link™ Iodoacetyl-LC-Biotin (Thermo) and 200 U/mL catalase. Lysis buffer 
was bubbled with nitrogen on ice to remove excess oxygen. Lysis buffer was added to 
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cell plates in a hypoxic camber containing nitrogen then wrapped in parafilm and 
incubated at 37°C for 90 min. Cells were then scraped, sonicated and centrifuged at 
14,000 rpm for 5 min to remove cellular debris. Samples were stored in -20°C.  
Following all biotin labeling experiments, protein was quantified using a 
bicinchoninic acid (BCA) protein assay (Pierce). An equal amount of protein from each 
sample was washed 5x with 20 mM Tris pH 7.4 using Amicon® Ultra 3k centrifugal spin 
columns (Millipore) to remove excess biotin. Protein was brought to a volume of 500 µL 
using WSB and added to high capacity NeutrAvadin agarose beads (Thermo) to isolate 
biotinylated proteins. Beads were incubated at 4°C overnight then washed as previously 
described [54]. NeutrAvadin beads were boiled for 10 min in elution buffer containing 
2% SDS, 1 mM EDTA, and 50 mM Tris-HCl at pH 8.0. Eluted protein was mixed with 
6xRSB and separated on SDS-PAGE for western blot.   
3.3.7. Mass Spectrometry 
Recombinant Src (Millipore T431M) was exposed to a 50 molar excess acrolein 
for 30 min. Samples were mixed with reducing sample buffer, run on SDS-PAGE then 
stained with Coomassie blue. Bands containing Src were removed and de-stained using 
25 mM NH4HCO3 in 50% acetonitrile. Gel pieces were dehydrated with 100% 
acetonitrile then dried using a speed vac. To reduce any disulfide bonds gel pieces were 
rehydrated with 10 mM dithiotreitol (DTT) in 100 mM NH4HCO3 for 1 hour at 57°C. To 
alkylate free cysteine thiols samples were incubated with 55 mM (10 mg/mL) 
iodoacetamide in 100 mM NH4HCO3 for 45 min in the dark. Gel pieces were then 
dehydrated with 100% acetonitrile and rehydrated with 100 mM NH4HCO3. After 
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dehydrating again with 100% acetonitrile gel pieces were dried using a speed vac. An in-
gel trypsin digestion was performed using 12 ng/µL trypsin in buffer containing 5% 
acetonitrile, 40 mM NH4HCO3 in H2O at 37°C for 12-18 hours. Peptides were extracted 
at room temperature by incubating gel pieces with 5% formic acid in H2O, 5% formic 
acid in 50:50 H2O:acetonitrile and 100% acetonitrile. Peptide solutions were then dried in 
a speed vac and analyzed using a Thermo-Fisher Scientific LTQ Linear Quadrupole Ion 
Trap-Oribitrap Mass Spectrometer Plus Liquid Chromatography, within the Vermont 
Genetics Network core facility at The University of Vermont. Peptides were identified 
using the SEQUEST database. 
3.3.8. Statistical Analysis 
To determine statistical significance data was analyzed by t-test or ANOVA based 
on the number of experimental groups. A p-value <0.05 was used as a cutoff of 







3.4.1 Acrolein activates Src.  
The canonical activation mechanism of Src involves the dephosphorylation of 
Y527 along with auto-phosphorylation at Y416 [65]. Since there is evidence that that Src 
can be activated through a non-canonical redox based mechanism after exposure to TGF-
β and 4-hydroxynonenal, we first tested if Src activation could occur following exposure 
to acrolein [39, 41]. H292 cells were exposed to varying concentrations of acrolein for 90 
min then lysed for analysis by western blot. We observed an increase in Y416 
phosphorylation only at 100 µM (Fig. 3.1A). One concern that can arise using higher 
concentrations of acrolein is cell toxicity, therefore we utilized the CellTiter-Glo® 
luminescence cell viability assay to measure acrolein toxicity over time. At 4 hours there 
was a slight decrease in cell viability at 200 µM and a significant decrease at 400 µM 
(Fig. 3S1) confirming that the doses used for experimentation were sub-toxic.  
To track activation over time, H292 cells were exposed to a bolus of 100 µM 
acrolein at various times from 15-120 min, and then lysed for analysis by western blot. 
Acrolein exposure resulted in an increase in Y416 phosphorylation beginning around 60 
min and was persistent through 120 min (Fig. 3.1B). Similar to activation by TGF-β and 
4-hydroxynonenal [41], acrolein exposure did not result in decreased phosphorylation of 
Y527 (Fig. 3.1B). Previous work in the van der Vliet laboratory has shown that 10 min 
exposure to ATP (100 µM) or EGF (10 ng/mL) results in increased Src phosphorylation 
and activation [66] and others have shown an increase in Src phosphorylation in response 
to 10% cigarette smoke extract (CSE) at 15 min [43]. Interestingly, we did not observe an 
54 
 
increase in Y416 phosphorylation at early time points (15-30 min, Fig 3.1B), which 
would suggest an alternative activation mechanism. We repeated time course experiments 
in immortalized human bronchial epithelial (HBE) cells and observed a similar pattern of 
activation as H292 cells, confirming previously described results were not cell type-
specific (Fig. 3.1C).  
We then measured phosphorylation of the downstream Src targets p120 catenin 
and Caveolin-1 to confirm the increase in Src phosphorylation corresponded with an 
increase in kinase activity. Phosphorylation of both caveolin-1 and p120 increased at the 
same time as Src Y416 phosphorylation, supporting our findings that Src is active (Fig. 
3.1B). To confirm that these two downstream phosphorylation targets were due to Src 
activation, we used AZD0530 (APExBIO) to inhibit Src kinase activity. By pretreating 
cells with AZD0530 we were able to prevent acrolein-induced phosphorylation of Y416 
on Src as well as the downstream phosphorylation of caveolin-1 and p120 detected 
through western blot (Fig. 3.1D).  Additionally, we show that acrolein induces EGFR 
phosphorylation at Y1068 that can be mediated through Src inhibition (Fig. 3.1D).  
We wanted to confirm that Src activation was not occurring through the activation 
of the EGF receptor since both Src and EGFR are known to activate each other resulting 
in a possible feed forward activation mechanism [66, 67]. Using the EGFR inhibitor 
AG1478 we were able to suppress the phosphorylation of tyrosine Y1068 following 
acrolein exposure (Fig 3.2). Looking at the activation of Src in the same experiment we 
see do not see any change in Y416 phosphorylation suggesting that EGFR activity is not 
involved in Src activation in response to acrolein (Fig 3.2).  
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Antioxidant response element (ARE) genes are induced in the cell as an adaptive 
cytoprotective response to oxidants and electrophilic stress. One ARE gene, heme 
oxygenase-1 is induced in response to acrolein and can be used as a measure of a positive 
acrolein exposure [68]. It has also been shown that HO-1 is induced in response to CS 
through activation of Src, therefore, we looked to determine if acrolein could induce HO-
1 through a Src dependent mechanism [69]. HO-1 induction was confirmed in our in vivo 
exposure model where we observed an increase in HO-1 mRNA, protein, and 
immunofluorescent staining in the lung epithelium after an acute exposure of 5 ppm 
acrolein for 4 hours (Fig 3.3A-C). When we silenced Src expression using siRNA we see 
attenuation of the HO-1 response to acrolein measured by western blot suggesting that 
acrolein is inducing HO-1 expression through a Src dependent mechanism (Fig 3.4).  
After demonstrating that acrolein could induce phosphorylation of Src targets we 
looked to determine if we could observe an increase in Src activity directly using an in 
vitro kinase activity assay with Src immunoprecipitated from H292 cells. H292 cells 
were exposed to 30 or 100 µM acrolein for 90 minutes then lysed in WSB. Src was 
immunoprecipitated then analyzed for kinase activity using the Antibody Beacon™ 
Tyrosine Kinase Assay Kit or analyzed by western blot for Y416 phosphorylation (Fig. 
3.5A and Fig. 3.5B). We found that acrolein exposure resulted in an increase in kinase 
activity along with an increase in Y416 phosphorylation showing direct evidence that 
acorlein is activating Src in a cellular context. 
Next we wanted to confirm activation directly using isolated recombinant Src in 
the same in vitro kinase activity assay. This allowed us to assess the effects of acrolein 
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directly on Src activity without the influence of any other cellular components. We 
exposed 1.5 ng Src to increasing concentrations of acrolein over time and assessed kinase 
activity using the Antibody Beacon™ Tyrosine Kinase Assay Kit (Thermo). We 
observed an increase in kinase activity at concentrations beginning at 30 µM increasing 
up to 200 µM suggesting that acrolein can activate Src directly (Fig. 3.5C). After 
exposing Src to acrolein the samples were mixed with 6X reducing sample buffer and 
analyzed by western blot to test if the increase in activation corresponded to an increase 
in phosphorylation at Y416. Despite being a cell free system we expected to see an 
increase in phosphorylation at Y416 due to autophosphorylation and excess ATP in the 
reaction buffer, however we did not observe any change in phosphorylation following 
acrolein exposure (Fig. 3.5D). This shows that acrolein is able to increase Src kinase 
activity independent of phosphorylation and further supports the need for a kinase assay 
to determine Src activity without relying on the presence of downstream phosphorylation 
targets.  
3.4.2. Acrolein binds directly to Src 
Acrolein is capable of binding to cysteine residues on redox sensitive proteins and 
therefore could play a role as a signaling molecule. Src contains a number of redox 
sensitive cysteine residues, therefore we hypothesized that acrolein is activating Src by 
directly binding to cysteine residues, forcing an open active conformation. We utilized a 
number of biochemical labeling approaches to show the presence of acrolein adducts on 
Src. To first identify acrolein adducts we utilized EZ-Link™ Hydrazide-Biotin (Thermo) 
to label protein carbonyls. When acrolein forms Michael adducts on cysteine residues it 
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increases the number of protein carbonyls that can be labeled with Hydrazide-Biotin. 
H292 cells were exposed to 100 µM acrolein for 30 min then labeled with Hydrazide-
Biotin to tag all acrolein adducts. After isolating proteins using high capacity 
NeutrAvadin agarose beads we probed for the presence of Src by western blot and 
observed an increase in Src in the acrolein-treated samples indicating acrolein adduction 
had occurred (Fig. 3.6A). Using a complementary approach, after we derivatized cell 
lysates with Hydrazide-Biotin we immunoprecipitated Src using an anti Src IgG 
antibody. After isolating Src we probed for the presence of biotin using a streptavidin 
HRP-conjugated antibody to measure BH-derivatized acrolein Michael adducts. In cells 
treated with acrolein we observed an increase in streptavidin, which is a measure of 
acrolein Michael adducts (Fig. 3.6B). After we identified acrolein adducts in our cell 
culture model we tested if we could identify acrolein adducts in vivo. We exposed 
C57BL6 mice to 7.5 ppm acrolein for 4 hours then isolated lung tissues. We made lung 
tissue homogenates and labeled acrolein Michael adducts using Hydrazide-Biotin. 
Following protein derivatization and purification using NeutrAvadin beads, analysis by 
western blot revealed an increase in Src after acrolein treatment (Fig. 3.6C). This 
indicates that acrolein is forming Michael adducts with Src in vivo.  
Because we observe acrolein-induced activation, based on Y416 phosphorylation 
of Src in H292 cells after 60 min (Fig 3.1B), we wanted determined whether the changes 
in Y416 phosphorylation corresponded to a change in the amount of acrolein adducts 
over time. Using the same Hydrazide-Biotin labeling technique as described above we 
exposed H292 cells to 100 µM acrolein for 30, 60, or 90 min to track the presence of 
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acrolein adducts over time. There was a significant increase in Src-acrolein adduct at 30 
min followed by a decrease by 90 minutes, suggesting a loss of acrolein adducts, or 
secondary reactions of acrolein adducts (Fig. 3.7A). To determine if the loss of acrolein 
adducts was associated with recovery of free cysteine thiols, we performed the same time 
course experiment using Iodoacetyl-LC-Biotin, which labels reduced cysteine residues. 
As expected, avadin-purified proteins from Iodoacetyl-LC-Biotin labeled cell lysates 
contained a strong band corresponding to Src in untreated control cells that was reduced 
after 30 min of acrolein exposure (Fig 3.7B). Reduction in band intensity persisted for 90 
min, indicating that the observed loss of Src-BH adducts was not due to recovery of free 
cysteine thiols (Fig. 3.7B). One possible explanation for a lack of free thiol recovery 
despite loss of acrolein adducts could be the oxidation of cysteine to a sulfenic acid. A 
sulfenic acid would block binding of Biotin-Hydrazide or Iodoacetyl-LC-Biotin. We 
utilized the probe DCP-Bio1 (Kerafast), which contains a biotin tag conjugated to 
dimedone to label sulfenic acids over time following treatment with acrolein. We observe 
a low level of sulfenylation in control cells that is increased by 30 min, and then slightly 
decreases by 90 minutes (Fig. 3.7C). Together these results show that acrolein is causing 
a modification of cysteine residues over time that are reversible and could play a role in 
kinase activation.  
The biotinylation analyses described above are able to give us qualitative 
information about what modifications might be occurring, but they are not able to 
identify specific amino acid residues that are being tagged. In order to determine the 
particular amino acids of interest we turn to tandem mass spectrometry (MS-MS) to give 
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us information on what modifications are present following acrolein exposures. Acrolein 
adduction to cysteine causes a 56.02621 Da mass increase that is unique from alkylation 
by other chemicals such as iodoacetamide (57.02146 Da) or N-Ethylmaleimide (125.0477 
Da). Previous work in the van der Vliet laboratory identified 769 proteins by mass 
spectrometry after isolating acrolein-exposed proteins with biotin hydrazide [20]. In order 
to identify acrolein adducts we first exposed recombinant Src to acrolein in a cell free 
system. Following an in gel digestion with trypsin we analyzed peptides for the presence 
of acrolein adducts using a (QC orbitrap) mass spectrometer. We observed about 80% 
protein coverage by LC-MS/MS and saw adducts present on cysteine residues 245, 277, 
400, 483 and 487 (Fig 3.8), supporting our results from western blot. Representative mass 
spectra of modified and unmodified C277 are shown in supplemental Fig 3S2. We then 
attempted to identify acrolein adducts on Src that was immunoprecipitated from H292 
cells. Following acrolein exposure, immunoprecipitation, and digestion with trypsin we 
were able identify a few peptides of Src, however the coverage was not sufficient to 
detect any acrolein adducts (Data not shown). After acrolein forms Michael adducts on 
cysteine residues its carbonyl can form a Schiff base with the terminal amine of lysine, 
cross linking the residues.  Resolution of cross-links results in the formation of a unique 
lysine adduct and regeneration of free cysteine thiol. Using LC-MS/MS we were able to 
detect acrolein-lysine adducts in Src following acrolein exposure suggesting lysine 






 Src kinase activation results in increased cellular proliferation, migration, and 
invasiveness through EGFR/MAPK signaling, increased turnover of focal adhesions, and 
increased matrix degradation [31]. As a result, increased Src kinase activity is commonly 
observed in cancer cells with increasing evidence of Src activation in COPD [30, 42]. 
The exact cause of Src activation remains uncertain since Src is a non-receptor tyrosine 
kinase and does not have a specific activating ligand. Recent research investigating this 
gap in knowledge suggests that activation occurs through the oxidation of cysteine 
residues [38, 70]. We hypothesized that acrolein activates Src by binding to cysteine 
residues thereby promoting an active state.  
In our experiments with acrolein we show that activation of Src occurs without 
dephosphorylation at Y527 (Fig 3.1B), consistent with other studies showing activation 
of Src by TGFβ1 through a redox dependent mechanism [39]. Increases in kinase activity 
were measured by detection of phosphorylated downstream target proteins and directly 
through a kinase activity assay (Fig. 3.1B, Fig 3.5B). Further, we show that acrolein 
binds to cysteine residues C245, C277, C483 and C487, which have been shown to be 
oxidized upon activation suggesting that modification of cysteine residues is a 
contributing factor to kinase activation (Fig. 3.8).  
The observed increase in kinase activity using recombinant protein were modest 
compared to differences observed by western blot, however directly comparing these 
measurements is difficult because in our recombinant system we used a synthetic peptide 
as the phosphorylation substrate and this is likely to have a different affinity than a Src 
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target such as p120 or caveolin-1. Second, in a cellular context SH2 and SH3 domain 
interactions with docking proteins may have an impact on kinase activity and substrate 
availability that is not present in our recombinant system.   
Interestingly, there is opposing evidence that cysteine oxidation can inhibit Src 
activity. It was suggested that oxidation of C277 results in an intermolecular disulfide 
bond forming a Src dimer that inhibits kinase activity [40]. When we expose cells to 
acrolein, cysteine residues are alkylated (Fig. 3.6) which would prevent oxidation of 
these residues and subsequent disulfide bond formation. We observe that biotin hydrazide 
labeling is reversed in vitro, and in our in vivo mouse model we observe a reduction in 
acrolein adducts over time if we wait to sacrifice mice 1, 4 or 24 hours after exposure to 
acrolein (O’Brien et al. unpublished data not shown). Using DCP-Bio1 labeling we show 
that acrolein exposure increases the oxidation of cysteine residues (Fig 3.7C). It is 
possible that Hydrazide-Biotin is labeling sulfenic acids as well, therefore we pretreated 
H292 cells with dimedone to block non-specific labeling of Hydrazide-Biotin. We 
observed the same change in alkylation following NeutrAvadin pull down when cells 
were pretreated with dimedone suggesting any oxidative modification by Hydrazide-
Biotin is negligible (Fig 3S2).  
The dephosphorylation of Y527 is known to occur through the activity of protein 
tyrosine phosphatases such as protein tyrosine phosphatase1-B (PTP1B) and SHP-2 that 
are known to redox sensitive [71]. The mechanism by which PTP1B dephosphorylates 
tyrosine residues utilizes a reactive cysteine residue that catalyzes the transfer of the 
phosphate to water. It’s been shown that acrolein inhibits the activity of PTP1B through 
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the alkylation of the cysteine residue involved in the phosphatase reaction mechanism 
[35]. Consistent with those findings, after labeling proteins with Hydrazide-Biotin and 
isolating with NeutrAvadin, we detect PTP1B by western blot confirming acrolein 
adduction (Fig. 3S3). The inhibition of PTP1B and other phosphatases can explain why 
we do not observe a decrease in Y527 phosphorylation after acrolein exposure (Fig 
3.1B). Additionally, the phosphatase known to remove pY416 (PTP-BAS) could be 
inhibited, which could lead to enhanced levels of phosphorylation [33].  
Of the nine cysteine residues found throughout Src, residue 277 is of particular 
interest because of its involvement in kinase activation and its close proximity to the A-
loop that contains Y416. Kinase activation by cysteine oxidation or alkylation could be 
explained by an increase in steric hindrance, forcing the A-loop into a conformation more 
permissive of phosphorylation. Under basal conditions it is predicted that there is a 3.5 Å 
distance between cysteine and tyrosine that is increased to 4.5 Å following acrolein 
adduction that could force the A-loop open (Fig 3.9). Giannoni et al. 2014 speculate that 
Src oxidation and enhanced kinase activation can be attributed to an intramolecular 
disulfide bond [70], however they do not provide direct evidence of an intermolecular 
disulfide. Since acrolein would prevent disulfide bond formation by adducting to cysteine 
residues, this would suggest that the activation we observe following acrolein exposure is 
not due to a disulfide bond, but due to the presence of a cysteine modification or adduct. 
Additional mass spectrometry analysis was performed identifying the remnants of 
cysteine-lysine cross-links (Fig 3.8). We were specifically interested in lysine 423 
because it is located in the kinase domain in close proximity to C277 and Y416. As an 
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alternative to cysteine modification inducing activation as described above, we 
hypothesized that a cysteine-lysine cross-link would form between C277 and K423 after 
acrolein exposure, and the resulting lysine modification would force the A-loop open. We 
were able to identify +38 Da mass shifts on lysine residues including K423 suggesting 
cross-link formation may play a role in kinase activation (Fig. 3.8).   
In the studies outlined here we show that acrolein exposure leads to activation of 
Src and the phosphorylation of p120 and caveolin 1 (Fig 3.1), which are known to play a 
role in maintaining proper airway epithelial junction stability. Src activation has long 
been established as a mediator of signaling events in cancer with increasing evidence 
supporting a redox based mechanism of activation. We demonstrate that acrolein directly 
binds to Src and results in direct kinase activation, providing evidence of a novel 
mechanism of Src activation (Fig 3.9).  Despite there being thousands of active chemicals 
present in CS we show that reactive aldehydes such as acrolein may play an important 
role in the development of lung diseases through mediating the activation of Src in these 
processes. Determining the molecular modifications underlying Src activation will help 
us understand how Src is involved in the development of lung disease and provide a 















Figure 3.1. Acrolein increases Src phosphorylation and activation in vitro. H292 cells 
were exposed to varying concentrations of acrolein for 90 min then analyzed by western 
blot (A). H292 and HBE cells were exposed to 100 µM acrolein at time points indicated 
then lysed for analysis by western blot (B and C). H292 cells were pretreated with 1 µM 
AZD0530 for 30 min then treated with 100 µM acrolein for 90 min. Src, EGFR, p120, 
and caveolin-1 phosphorylation was measured by western blot (D). 
  
Figure 5. Src is activated by acrolein. H292 cells exposed to varying concentrations of acrolein
for 90 min show an increase in Src phosphorylation only at 100μM (A). Exposure to acrolein
increases Src phosphorylation at Y416 independent of phosphorylation at Y527 starting 60 min
following acrolein exposure, which also tracks with increased phosphorylation of Src targets
CaveolinK1 and p120 (B). Increased phosphorylation of Src, p120 catenin, and caveolinK1 was
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Figure 3.2. Acrolein induced Src phosphorylation occurs upstream of EGFR kinase 
activation. H292 cells were pretreated with the EGFR inhibitor AG1478 at a 
concentration of 1 µM for 30 min then exposed to 30 or 100 µM acrolein for 90 min. 
Analysis by western blot reveals inhibition of EGFR phosphorylation without inhibition 






















Figure 3.3. Acute acrolein exposure induces HO-1 in vivo. Mice were exposed to 5 
ppm acrolein for 4 hours then sacrificed. HO-1 was analyzed by qRT-PCR (A), western 
blot (B), and immunofluorescent staining of lung tissue sections (C). blue=DAPI, red = 































Figure 3.4. Acrolein induced HO-1 expression is mediated through Src. H292 cells 
were transfected with non-specific (NS) or Src siRNA then exposed to acrolein for 4 














Figure 3.5. Src activity is increased after exposure to acrolein. H292 cells were 
exposed to 30 or 100 µM acrolein for 90 min followed by a Src immunoprecipitation. IP 
Src was then tested for kinase activity (A) n=2 *p<0.05, and levels of Y416 
phosphorylation by western blot (B). Recombinant Src was exposed to acrolein then 
measured for activity using the Antibody Beacon™ Tyrosine Kinase Assay Kit (C) n=5 
*p<0.05. Recombinant Src was exposed to varying concentrations of acrolein then 
analyzed by western blot for Y416 phosphorylation (D).  
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Figure 3.6. Acrolein adducts on Src can be detected in vitro and in vivo. Following 
exposure to acrolein, H292 cell lysates were labeled with Hydrazide-Biotin to tag 
acrolein adducts. Labeled proteins were isolated using NeutrAvadin agarose beads and 
identified by western blot (A). Conversely, Src was immunoprecipitated from biotin-
labeled cell lysates using an α-Src antibody and then probed for the presence of biotin 
using streptavidin-HRP (B). Whole lung homogenates taken from mice exposed to 7.5 
ppm acrolein for 4 hours were labeled with biotin hydrazide, purified with NeutrAvidin 
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Figure 3.7. Cysteine modifications by acrolein are reversed over time.  H292 cells 
were exposed to 100 µM acrolein for various times over 90 min. Proteins in cell lysates 
were labeled with Hydrazide-Biotin (A), DCP-Bio1 (B) and Iodoacetyl-LC-biotin (C) to 
label and isolate carbonyls, sulfenic acids and free thiols respectively. Labeled proteins 





































Figure 3.8. Acrolein adducts are detectable by mass spectrometry. Recombinant Src 
protein was exposed to a 50 molar excess of acrolein, run on a reducing SDS-page gel 
and stained with Coomassie blue. An in gel digested was performed with trypsin then 
samples were subjected to LC-MS/MS. Acrolein was observed on the cysteine residues 
listed. Observed mass (MH+), charge (+Z), and cross correlation score are given for each 
peptide. Asterisk (*) next to residue number indicates a residue involved in redox 





































Figure 3.9. Proposed Src activation mechanism. Under basal conditions Src is held in a 
closed inactive conformation. Upon activation, Src unfolds and allows for 
autophosphorylation at Y416. We propose that acrolein binds to C277 forcing the 
activation loop open through steric interactions between Y416 and K423, resulting in a 





























Figure 3S1. Cell viability after acrolein exposure. H292 cells were exposed to acrolein 
for 4 hours. The effects of acrolein on cell viability was analyzed by CellTiter-Glo® 
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Figure 3S2. Representative LC-MS/MS spectra. Recombinant Src was exposed to a 50 
molar excess acrolein and analyzed by LC-MS/MS with a mass tolerance of 0.02 Da.  
Peptide spectrum (A) is shown with a parent ion mass of 2155.96 Da while peptide 















Figure 3S2. Dimedone pretreatment does not reduce Hydrazide-Biotin labeling. 
H292 cells were incubated with 1 mM dimedone for 1 hour. Cells were then exposed to 
acrolein and labeled with Hydrazide-Biotin. After proteins were isolated with 


















Figure 3S3. Acrolein adducts to PTP1B.  H292 cells were exposed to 100 µM acrolein 
for 30, 60, or 90 min. Proteins were labeled with Hydrazide-Biotin and isolated with 
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS 
4.1 Summary 
Src is involved in regulating E-cadherin and has been shown to mediate the 
development of EMT in response to cigarette smoke [43]. Loss of E-cadherin is 
associated with EMT, and increasing evidence shows EMT is involved in the 
development of COPD as well [72].  We tested the effects of acrolein on epithelial barrier 
function using mouse tracheal epithelial cells seeded in Transwell® cell culture dishes 
measuring trans epithelial resistance and permeability to FITC-Dextran. As expected we 
show that acrolein exposure results in a weakening of the epithelium (Fig. 2.1). We 
demonstrate that Src activation is a key mediator in this response since Src inhibition 
with the inhibitor PP2 could completely prevent loss of epithelial barrier integrity (Fig 
2.1). Further, we show that loss of barrier function corresponds to a subsequent loss of 
epithelial junction proteins E-cadherin and ZO-1, and the loss of protein could be 
attenuated through Src inhibition (Fig 2.1C).  
It’s been shown that cigarette smoke exposure leads to the development of EMT 
and lung tissue destruction through activation of Src [42, 43].  Preliminary experiments 
have shown that chronic acrolein exposure leads to a reduction in E-cadherin (Fig. 2.5), 
which is a hallmark of EMT and associated with the development of COPD. In our in 
vivo chronic exposure models we were not able to replicate preliminary findings that 
acrolein exposure resulted in decreased E-cadheirn and increased vimentin expression in 
association with increased Src phosphorylation. Despite these findings we show that 
81 
 
acrolein increases MMP9 and KC expression  (Fig 2.6) and that acrolein induces an HO1 
response (Fig 3.3). It should be noted that the exposure system had been slightly modified 
between preliminary work and these attempts at replication due to a change in facilities, 
although measures were taken to recreate the model to the best of our abilities. Future 
experiments will be required to confirm current and past findings.  
We began these studies characterizing the ability of acrolein to activate the non-
receptor tyrosine kinase Src in lung epithelial cells. We exposed cells to acrolein and 
observed an increase in autophosphorylation of Src as well as an increase in 
phosphorylation of downstream Src targets confirming Src was active (Fig 3.1). 
Interestingly Src activity increased without a reduction in the inhibitory phosphate site of 
Y527 (Fig 3.1B), which is consistent with a mechanism observed in redox activation of 
kinase activity [38, 41]. Using the chemical Src inhibitor AZD0530 we showed that 
downstream phosphorylation could be blocked confirming phosphorylation was mediated 
through Src (Fig 3.1D). We wanted to confirm that Src was the direct target of activation 
by acrolein, so used recombinant Src to show that activity increases in response to 
acrolein in a cell free system (Fig 3.5C).  
Research has shown evidence that cysteine oxidation is involved in activation of 
Src activity [38]. Based on these findings and the chemistry involved between acrolein 
and cysteine residues, we investigated the ability of acrolein to bind to Src and further 
identify which specific residues were being adducted. Using biochemical-labeling 
strategies involving Hydrazide-Biotin and NeutrAvadin purification we demonstrated that 
acrolein binds to Src both in vitro and in vivo (Fig 3.6). We used tandem mass 
82 
 
spectrometry to determine which specific residues were adducted by acrolein (Fig. 3.8). 
We show that acrolein binds to cysteine residues that have previously been implicated in 
the oxidative activation of Src supporting our hypothesis that acrolein activates Src 
through a direct modification of cysteine residues. Studies outlined thus far were 
designed to determine the ability of acrolein to activate Src and provide evidence of a 
potential mechanism by which acrolein causes Src activation.  
Together our results show that acrolein activates the Src kinase likely through 
direct modification of redox-sensitive cysteine residues. This demonstrates a novel 
activation mechanism by which acrolein adducts force the kinase domain open allowing 
for autophosphorylation and activation independent of the inhibitory actions of Y527. 
Additionally we show that acrolein induced epithelial injury and remodeling occurs 
through activation of Src, further demonstrating the involvement of Src activation in the 
development of lung disease. This work has important implications characterizing 
acrolein alongside ROS as a contributing factor in Src activation providing valuable 




4.2 Future Directions 
 We have shown that acrolein activates Src and binds to specific cysteine residues 
that have been implicated in the activation of kinase activity. We have also shown that 
acute acrolein exposure induces epithelial barrier disruption in vitro and in vivo mediated 
through the activation of Src. Further, chronic acrolein exposure in vitro resulted in the 
loss of E-cadherin, which is similarly observed in response to CS. Experiments using 
chemical Src inhibitors such as PP2 or AZD0530 in conjunction with acrolein exposure 
in vivo will need to be repeated to provide more replicates and to ensure changes in FITC 
leakage are consistent. Follow up studies involving chronic acrolein exposure will also be 
conducted using a Src deficient mouse model to test the importance of Src activation in 
responses generated by acrolein exposure.  
In our studies we determined that acrolein activates Src and directly binds to 
cysteine residues C245, C277, C400 and C487, which are involved in and oxidative 
activation mechanism [38]. In future studies we plan to expand upon this work by 
utilizing cysteine to alanine mutants to determine which specific residues are involved in 
increasing kinase activity in response to acrolein. Studies will be conducted using 
recombinant Src mutants purified from E.coli and in H292 cells transfected with plasmids 
containing different Src mutants. We can perform further experiments with these mutants 
addressing aspects of cell migration or wound healing in response to acrolein to assess 
the role of Src activation in a more physiologically relevant context. Identifying the 
specific residues involved in activation will help determine a mechanism describing Src 
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activation and can provide insight into what interactions are occurring within Src that 
lead to kinase activation.  
 Current mass spectrometry experiments have identified cysteine residues as direct 
targets for acrolein adduction, although experiments thus far have identified adducts only 
at single time points. Additionally, using our current models we cannot determine the 
degree of alkylation within a sample, or quantitative changes in alkylation over time. We 
would like take advantage of isotopic labeling strategies to quantify acrolein adducts over 
time using mass spectrometry and to see if increases in Src phosphorylation can be 
correlated to the rise or fall of acrolein adducts on specific cysteine residues. These 
experiments can be conducted using commercially available reagents with little to no 
alteration in initial experimental procedures.  
We first observed an increase in Src oxidation in experiments using the dimedone 
based biotin tag DCP-Bio1 (Fig. 3.7C).  It was not too surprising to see a slight rise in 
oxidation following acrolein exposure since acrolein binds and depletes many cellular 
antioxidants, specifically GSH [23]. With a loss of cellular antioxidants we would expect 
to see a rise in the levels of ROS within the cell creating a more oxidizing environment. 
Since Src is activated in response to reactive oxygen species that oxidize cysteine 
residues we plan on investigating the involvement of ROS on Src activation following 
acrolein exposure. Initial experiments will utilize superoxide indicators such as 
hydroethidine or dichlorofluorescein (DCF) that can track ROS production in plate reader 
assays or confocal microscopy. ROS scavengers such as catalase or NAC will be used to 
characterize the impact of ROS on Src activation in response to acrolein. Further, we can 
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use mass spectrometry to identify oxidized cysteine residues on Src following 
immunoprecipitation from cell lysates after acrolein exposure. Research investigating the 
interplay between alkylation and oxidation will help determine mechanisms involved in 
protein activation. In the future we hope to expand upon the current completed studies to 
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